Patient characteristics
| . | Age ≤70 y, N = 5380 . | Age >70 y, N = 542 . | Total, N = 5922 . | P . |
|---|---|---|---|---|
| Age, y | <.0001* | |||
| Mean (SD) | 53.7 (10.10) | 74.0 (3.00) | 55.6 (11.29) | |
| Median (range) | 55.0 (17.8, 70.0) | 73.2 (70.0, 90.1) | 56.3 (17.8, 90.1) | |
| Sex, n (%) | .0042† | |||
| Female | 2661 (49.5) | 303 (55.9) | 2964 (50.1) | |
| Male | 2719 (50.5) | 239 (44.1) | 2958 (49.9) | |
| ECOG PS, n (%) | .0004† | |||
| 0-1 | 4299 (95.0) | 444 (91.2) | 4743 (94.6) | |
| ≥2 | 227 (5.0) | 43 (8.8) | 270 (5.4) | |
| Missing | 854 | 55 | 909 | |
| FLIPI, n (%) | <.0001† | |||
| Low | 989 (21.8) | 12 (2.6) | 1001 (20.0) | |
| Intermediate | 1753 (38.7) | 124 (26.7) | 1877 (37.5) | |
| High | 1792 (39.5) | 329 (70.8) | 2121 (42.4) | |
| Missing | 846 | 77 | 923 | |
| FLIPI score without age, n (%) | .17† | |||
| 0 | 145 (3.4) | 12 (2.8) | 157 (3.4) | |
| 1 | 1148 (27.1) | 115 (26.9) | 1263 (27.1) | |
| 2 | 1786 (42.1) | 163 (38.2) | 1949 (41.8) | |
| 3 | 922 (21.7) | 103 (24.1) | 1025 (22.0) | |
| 4 | 240 (5.7) | 34 (8.0) | 274 (5.9) | |
| Missing | 1139 | 115 | 1254 | |
| Ann Arbor stage, n (%) | .60† | |||
| I/II | 273 (5.2) | 31 (5.7) | 304 (5.3) | |
| III/IV | 4960 (94.8) | 509 (94.3) | 5469 (94.7) | |
| Missing | 147 | 2 | 149 | |
| Nodal sites, n (%) | <.0001† | |||
| <5 | 1248 (35.0) | 171 (45.6) | 1419 (36.0) | |
| ≥5 | 2314 (65.0) | 204 (54.4) | 2518 (64.0) | |
| Missing | 1818 | 167 | 1985 | |
| LDH at baseline, n (%) | .0159† | |||
| >ULN | 1394 (35.7) | 164 (41.8) | 1558 (36.3) | |
| ≤ULN | 2511 (64.3) | 228 (58.2) | 2739 (63.7) | |
| Missing | 1475 | 150 | 1625 | |
| HGB at baseline, n (%) | <.0001† | |||
| ≥12 g/dL | 3309 (81.4) | 300 (72.8) | 3609 (80.6) | |
| <12 g/dL | 756 (18.6) | 112 (27.2) | 868 (19.4) | |
| Missing | 1315 | 130 | 1445 | |
| β-2 at baseline, n (%) | <.0001† | |||
| >ULN | 928 (48.5) | 120 (67.8) | 1048 (50.2) | |
| ≤ULN | 984 (51.5) | 57 (32.2) | 1041 (49.8) | |
| Missing | 3468 | 365 | 3833 | |
| Rituximab, n (%) | .0898† | |||
| No rituximab | 2236 (41.8) | 204 (38.0) | 2440 (41.4) | |
| Rituximab | 3117 (58.2) | 333 (62.0) | 3450 (58.6) | |
| Missing | 27 | 5 | 32 |
| . | Age ≤70 y, N = 5380 . | Age >70 y, N = 542 . | Total, N = 5922 . | P . |
|---|---|---|---|---|
| Age, y | <.0001* | |||
| Mean (SD) | 53.7 (10.10) | 74.0 (3.00) | 55.6 (11.29) | |
| Median (range) | 55.0 (17.8, 70.0) | 73.2 (70.0, 90.1) | 56.3 (17.8, 90.1) | |
| Sex, n (%) | .0042† | |||
| Female | 2661 (49.5) | 303 (55.9) | 2964 (50.1) | |
| Male | 2719 (50.5) | 239 (44.1) | 2958 (49.9) | |
| ECOG PS, n (%) | .0004† | |||
| 0-1 | 4299 (95.0) | 444 (91.2) | 4743 (94.6) | |
| ≥2 | 227 (5.0) | 43 (8.8) | 270 (5.4) | |
| Missing | 854 | 55 | 909 | |
| FLIPI, n (%) | <.0001† | |||
| Low | 989 (21.8) | 12 (2.6) | 1001 (20.0) | |
| Intermediate | 1753 (38.7) | 124 (26.7) | 1877 (37.5) | |
| High | 1792 (39.5) | 329 (70.8) | 2121 (42.4) | |
| Missing | 846 | 77 | 923 | |
| FLIPI score without age, n (%) | .17† | |||
| 0 | 145 (3.4) | 12 (2.8) | 157 (3.4) | |
| 1 | 1148 (27.1) | 115 (26.9) | 1263 (27.1) | |
| 2 | 1786 (42.1) | 163 (38.2) | 1949 (41.8) | |
| 3 | 922 (21.7) | 103 (24.1) | 1025 (22.0) | |
| 4 | 240 (5.7) | 34 (8.0) | 274 (5.9) | |
| Missing | 1139 | 115 | 1254 | |
| Ann Arbor stage, n (%) | .60† | |||
| I/II | 273 (5.2) | 31 (5.7) | 304 (5.3) | |
| III/IV | 4960 (94.8) | 509 (94.3) | 5469 (94.7) | |
| Missing | 147 | 2 | 149 | |
| Nodal sites, n (%) | <.0001† | |||
| <5 | 1248 (35.0) | 171 (45.6) | 1419 (36.0) | |
| ≥5 | 2314 (65.0) | 204 (54.4) | 2518 (64.0) | |
| Missing | 1818 | 167 | 1985 | |
| LDH at baseline, n (%) | .0159† | |||
| >ULN | 1394 (35.7) | 164 (41.8) | 1558 (36.3) | |
| ≤ULN | 2511 (64.3) | 228 (58.2) | 2739 (63.7) | |
| Missing | 1475 | 150 | 1625 | |
| HGB at baseline, n (%) | <.0001† | |||
| ≥12 g/dL | 3309 (81.4) | 300 (72.8) | 3609 (80.6) | |
| <12 g/dL | 756 (18.6) | 112 (27.2) | 868 (19.4) | |
| Missing | 1315 | 130 | 1445 | |
| β-2 at baseline, n (%) | <.0001† | |||
| >ULN | 928 (48.5) | 120 (67.8) | 1048 (50.2) | |
| ≤ULN | 984 (51.5) | 57 (32.2) | 1041 (49.8) | |
| Missing | 3468 | 365 | 3833 | |
| Rituximab, n (%) | .0898† | |||
| No rituximab | 2236 (41.8) | 204 (38.0) | 2440 (41.4) | |
| Rituximab | 3117 (58.2) | 333 (62.0) | 3450 (58.6) | |
| Missing | 27 | 5 | 32 |